RT enhances CAR T-cell therapy through STING activation. (A) Working model: time line and schematic representation of in vivo A20 tumor–bearing mice treated with RT followed by CART-19 cell injection with or without the STING antagonist H-151. All mice of all groups were treated with the same CP lymphodepletion regimen. (B-C) Tumor growth from irradiated and abscopal tumors (n = 8). (D) CD45.2^–/CD3⁺/CD45.1⁺ T-cell infiltration in irradiated and abscopal tumors, representing the CART-19 cells. (E) CD45.2⁺/CD11c⁺ DC infiltration in irradiated and abscopal tumors. (F-G) IFN-γ spots after overnight stimulation of tumor or spleen cell suspensions with AH1 peptide with or without anti–MHC I antibody. Graphs show the mean ± SEM. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. Data are representative of 1 experiment.